By Sheri Kasprzak
New York, March 6 - Regenerx Biopharmaceuticals, Inc. said it arranged a direct placement for $7,283,385.
The offering includes 2,591,952 shares at $2.81 each.
The investors will also receive warrants for 907,182 shares, exercisable at $4.06 each.
The shares will be offered under the company's shelf registration.
RBC Capital Markets Corp. is the placement agent.
The deal is expected to close March 15.
Based in Bethesda, Md., Regenerx is a biopharmaceutical company focused on treatments for chronic viral infections, cancer and autoimmune disease.
| Issuer: | Regenerx Biopharmaceuticals, Inc.
|
| Issue: | Stock
|
| Amount: | $7,283,385
|
| Shares: | 2,591,952
|
| Price: | $2.81
|
| Warrants: | For 907,182 shares
|
| Warrant strike price: | $4.06
|
| Placement agent: | RBC Capital Markets Corp.
|
| Pricing date: | March 6
|
| Settlement date: | March 15
|
| Stock symbol: | AMEX: RGN
|
| Stock price: | $3.15 at close March 6
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
